- Trial phase
- Pilot study (proof-of-concept, equivalent to early Phase 1/2)
- Time to market
- KB113 is in early-stage development with no registered Phase 2/3 trial and no defined regulatory timeline. The company is in discussions with the FDA to determine the clinical development plan. If a pivotal program is agreed upon and initiated in 2027, potential approval would likely be several years away, barring a breakthrough or accelerated pathway.
- Why 3/10
- KB113 has no hard dated catalyst in the next ~12 months: the pilot study data was already reported (October 15, 2026), and the company is in early FDA discussions to define the clinical development plan. No PDUFA date, pivotal readout, or AdComm is scheduled. KB113 is an early-stage program at a commercial-stage company with multiple other pipeline assets, so its impact on the stock is limited relative to VYJUVEK revenue and later-stage readouts (KB803, KB801).
Watch for Krystal Biotech's announcement of FDA alignment on KB113's clinical development plan, which will define whether the program advances into a registrational trial or requires additional dose-finding studies. The small pilot (n=3) provides proof-of-concept but the regulatory path and timeline remain undefined, making KB113 a pipeline story rather than a near-term catalyst.
Price Chart
Executive Summary
KB113 is an investigational intratumoral gene therapy from Krystal Biotech (KRYS) that uses a modified, non-replicating herpes simplex virus to deliver IL-2 and IL-12 directly into skin tumors. On October 15, 2026, the company reported positive proof-of-concept data from a 3-patient pilot study in Gorlin syndrome, a rare genetic condition that causes numerous basal cell carcinomas. Over 83% of assessed lesions regressed, including tumors that were never directly injected, and all adverse events were mild or moderate. The company has initiated FDA discussions to define the path to advanced clinical development, but no specific Phase 2/3 trial design, timeline, or PDUFA date has been set. KB113 is an early-stage program at a commercial-stage company whose primary value driver is the approved product VYJUVEK (dystrophic epidermolysis bullosa), which generated $127.3M in Q3 2026 revenue.
How It Works
KB113 is a modified herpes simplex virus (HSV-1) that has been engineered to be unable to replicate or cause disease. It is injected directly into skin tumors, where it delivers genes for two immune-stimulating proteins (IL-2 and IL-12). These proteins recruit and activate the patient's own immune cells to attack the injected tumor and, through a systemic effect called the abscopal effect, also attack tumors elsewhere in the body that were never injected.
Trial Status
A 3-patient, multicenter, single-arm, open-label pilot study in Gorlin syndrome patients with BCCs was completed. Results were reported on October 15, 2026, and presented at the PeDRA Annual Conference (October 15-17, 2026). The company has initiated FDA discussions for the next stage of clinical development. No Phase 2 or Phase 3 trial has been registered on ClinicalTrials.gov as of November 2, 2026.
The Two-Sided Case
Upcoming Catalysts
- FDA alignment announcement on KB113's clinical development plan (timing unknown, likely months away)
- Initiation of a Phase 2 or registrational trial for KB113 in Gorlin syndrome (no date set)
- Interim or topline data from any future KB113 trial (no date set)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Krystal Biotech, Inc. PRESS-RELEASE KRYS ·Originating report